Only relatively uncomplicated drug or biologic applications that can be quickly reviewed are suitable for the US Food and Drug Administration’s Real-Time Oncology Review program, the agency clarifies in a guidance on the expedited pathway.
To be considered for RTOR, “no aspect of the submission is likely to require a longer review time,” such as for a new Risk Evaluation and Mitigation Strategy or an...